Citation:Rubenstein JH, Inadomi JM 2006

From Cancer Guidelines Wiki

Citation


Rubenstein JH, Inadomi JM. Defining a clinically significant adverse impact of diagnosing Barrett's esophagus. J Clin Gastroenterol 2006 Feb;40(2):109-15 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16394870.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Is surveillance cost-effective for follow-up of patients with BO?Dr Louisa Gordoncompleted
For which populations is screening for BO cost-effective?Professor Jon Emery MA, MBBCh, FRACGP, MRCGP, DPhilcompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:Is surveillance cost-effective for follow-up of patients with BO?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Is surveillance cost-effective for follow-up of patients with BO?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:For which populations is screening for BO cost-effective?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:For which populations is screening for BO cost-effective?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. For which populations is screening for BO cost-effective?